Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Core Insights - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing advanced antibody engineering and therapeutic combinations for treating Inflammatory Bowel Disease (IBD) and other immune-mediated diseases [1][3] Group 1: Company Overview - Spyre Therapeutics aims to create next-generation products for IBD and other immune-mediated diseases through best-in-class antibody engineering, dose optimization, and rational therapeutic combinations [3] - The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 [3] Group 2: Upcoming Events - Management will participate in a fireside chat and investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 10:00 a.m. ET [2] - Live audio webcasts and replays of the events will be available on the Spyre investor events website [2]